Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan

PR Newswire July 29, 2013

BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs

PR Newswire July 23, 2013

BioDelivery Sciences Adds $20 Million with Debt Financing

PR Newswire July 8, 2013

BioDelivery Sciences to Present at the 8th Annual JMP Securities Healthcare Conference

PR Newswire July 3, 2013

BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA

PR Newswire June 10, 2013

BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference

PR Newswire June 5, 2013

BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference

PR Newswire May 28, 2013

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials

PR Newswire May 9, 2013

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire May 7, 2013

BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors

PR Newswire April 29, 2013

BioDelivery Sciences Expands Product Pipeline with Acquisition of Patented Topical Clonidine Gel for the Treatment of Painful Diabetic Neuropathy

PR Newswire March 26, 2013

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report

PR Newswire March 18, 2013

BioDelivery Sciences to Present at the 25th Annual ROTH Conference

PR Newswire March 13, 2013

BioDelivery Sciences to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire March 1, 2013

INVESTOR ALERT: Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate BioDelivery Sciences International, Inc., Following Notice of Non-Reliance of Financial Statements and Restatement

Business Wire February 28, 2013

BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event

PR Newswire February 27, 2013

BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference

PR Newswire February 5, 2013

BioDelivery Sciences Announces Completion of BNX Safety Study

PR Newswire January 22, 2013